Samar Mahmoud, MS

Researchers from the Graduate Institute of Clinical Medical Science have established a potential link between hepatitis C virus and cataract development.

Johns Hopkins University School of Medicine researchers provide insight on how HCV evades the human immune response and why developing an HCV vaccine has been difficult.

Researchers posit that increased direct-acting antiviral (DAA) coverage can work to completely eradicate hepatitis c virus (HCV) in some populations of HIV-positive coinfected patients.

Should practitioners administer these drugs to patients with advanced liver disease, despite the risks?

It is becoming increasingly clear that the hepatitis C virus (HCV) can wreak havoc on a patient’s psychological well-being, even in the absence of a continued viral presence.

Researchers recently examined data from 21k+ patients in the Veterans Affairs healthcare system to determine if a correlation exists between race or ethnicity and the efficacy of direct-acting antiviral (DAAs) for the treatment of hepatitis C (HCV).

In a phase 3 clinical trial, Japanese patients with chronic hepatitis C (HCV) infection without liver cirrhosis were able to achieve high sustained viral response rates after taking an investigational HCV drug from AbbVie.

The European Medicines Agency (EMA) released guidelines recommending screening for hepatitis B in patients who are infected with hepatitis C prior to starting treatment with direct-acting antivirals.

Researchers from France recently found that higher base levels of vitamin D were not associated with a stronger immune response in HIV-infected patients.

Researchers from Purdue University have discovered a connection between hepatitis B (HBV) infection and liver cancer.